The statistic displays the quarterly share of Celltrion's Remsima in the European market from the first quarter of 2015 to the second quarter of 2018. As of Q2 2018, the Remsima products from South Korean biopharmaceutical company Celltrion took up around 54 percent within the European market, increased from 53 percent in the previous quarter.
Quarterly share of Celltrion's Remsima in the European market from 1st quarter 2015 to 2nd quarter 2018
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Single Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$59 $39 / Month *
in the first 12 months
Corporate Account
Full access
Corporate solution including all features.
* Prices do not include sales tax.
Further Content: You might find this interesting as well
Statistics
- Market share of Celltrion's Truxima in Europe Q2 2017-Q2 2018
- Celltrion R&D investment South Korea 2013-2017
- Biosimilar market size Japan 2018-2030
- Biopharmaceutical market size forecast Japan 2011-2020
- Latin America: biopharmaceuticals revenue 2020-2025
- Peak sales per new biopharmaceutical asset 2010-2020
- Trade balance in high technology sectors of EU countries 2020
- Revenue forecast for global biologics market 2016-2022
- Global biopharma non-cold chain product sales 2016-2024
- Loss of Lantus sales to U.S. biosimilars 2015-2017
- Worldwide biopharma M&A transaction volume by location 2015-2019
- Breakdown of transport modes in biopharma cold chain logistics 2019
- Priorities of life sciences logistics leaders in biopharma cold chain logistics 2019
- Average temperature of excursion shipments in biopharma cold chain logistics 2019
- Global biopharma logistics spending breakdown by type 2019
- Italy: estimated market value of biosimilars 2018-2022, by type
- Average per-patient biopharmaceutical clinical trial costs in the U.S. 2013, by phase
- States with the most biopharmaceutical clinical trials in the U.S. in 2013
- Biopharmaceutical companies by turnover size band in the UK 2017
- Economic impact of biopharmaceutical industry-sponsored clinical trials U.S. 2013
Mirae Asset. (December 5, 2018). Quarterly share of Celltrion's Remsima in the European market from 1st quarter 2015 to 2nd quarter 2018 [Graph]. In Statista. Retrieved June 26, 2022, from https://www.statista.com/statistics/1000627/south-korea-celltrion-remsima-market-share-in-europe/
Mirae Asset. "Quarterly share of Celltrion's Remsima in the European market from 1st quarter 2015 to 2nd quarter 2018 ." Chart. December 5, 2018. Statista. Accessed June 26, 2022. https://www.statista.com/statistics/1000627/south-korea-celltrion-remsima-market-share-in-europe/
Mirae Asset. (2018). Quarterly share of Celltrion's Remsima in the European market from 1st quarter 2015 to 2nd quarter 2018 . Statista. Statista Inc.. Accessed: June 26, 2022. https://www.statista.com/statistics/1000627/south-korea-celltrion-remsima-market-share-in-europe/
Mirae Asset. "Quarterly Share of Celltrion's Remsima in The European Market from 1st Quarter 2015 to 2nd Quarter 2018 ." Statista, Statista Inc., 5 Dec 2018, https://www.statista.com/statistics/1000627/south-korea-celltrion-remsima-market-share-in-europe/
Mirae Asset, Quarterly share of Celltrion's Remsima in the European market from 1st quarter 2015 to 2nd quarter 2018 Statista, https://www.statista.com/statistics/1000627/south-korea-celltrion-remsima-market-share-in-europe/ (last visited June 26, 2022)